Clinical Commander

Back to dossier
cardio.nstemi.octogenarian-conservative.v1PRODUCTION
cardio.nstemi.octogenarian-conservative.v1

Octogenarian NSTE-ACS — conservative strategy

cardiologyacuteadultgeriatric
Hard-required inputs
0 / 13
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm NSTE-ACS in age ≥80; flag elderly-specific shared decision (invasive vs conservative) per ACC/AHA 2025; route to parent cardio.nstemi.core.v1 for the universal regimen with elderly-specific antiplatelet + AKI + DAPT-duration overrides

Inputs
2
Actions
0
Advance rule
Set
Advance when

NSTE-ACS confirmed in ≥80 patient

Patient inputs (13)

Baseline EF + RWMA + valvular screen; conservative path still wants echo for risk stratification

Age ≥80 defines this cohort; prasugrel CONTRAINDICATED >75 per FDA; ticagrelor still acceptable but bleed risk higher per PLATO subgroup

Prasugrel CONTRAINDICATED <60 kg; enoxaparin weight-based; falls + low weight = HBR per ARC-HBR

≥1 fall in last 6 mo = ARC-HBR minor; gates DAPT duration + intensity

Prior major bleed = ARC-HBR major; absolute contraindication to prasugrel (also age >75 / wt <60 per FDA)

Polypharmacy ADE screen (Beers); concomitant OAC alters DAPT plan (AUGUSTUS); SSRI + NSAID + steroids amplify bleed

ESC 2023 0/1-h hsTn confirms NSTEMI within elderly cohort; chronic elevation common in CKD/HF — dynamic delta required

eGFR drives contrast nephropathy risk + enoxaparin/DOAC dosing; KDIGO 2026 pre-hydration if proceeding

Hgb <11 g/dL female / <12 male = ARC-HBR major; gates DAPT duration

<100k = ARC-HBR major; affects antiplatelet plan

Serial ECG for dynamic changes — escalates to invasive even in elderly per ACC/AHA 2025 high-risk feature

Hypotension overrides conservative path → re-categorise to very-high-risk and reassess shared decision

Clinical Frailty Scale (Rockwood) or Fried phenotype drives invasive-vs-conservative shared decision per ACC/AHA 2025 + SENIOR-RITA

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninghemodynamic_or_electrical_instability_overrides_conservative_path
    SBP <90 with hypoperfusion OR sustained VT/VF in octogenarian NSTE-ACS — overrides conservative shared decision and re-frames toward invasive (functional baseline permitting)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremajor_bleed_on_antiplatelet_in_octogenarian_nsteacs
    BARC 3+ or BARC 2 with hemodynamic compromise during DAPT in octogenarian NSTE-ACS — gates immediate antiplatelet hold + bleed source workup + DAPT-duration shortening
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecontrast_nephropathy_risk_egfr_below_30
    eGFR <30 + cath being considered in octogenarian — high contrast nephropathy + dialysis-initiation risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatefrailty_cfs_ge_6_with_cath_consideration
    Clinical Frailty Scale ≥6 (moderately frail / requires assistance with all outside activities) + cath being considered — shared decision must explicitly weigh procedural mortality + functional decline risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepolypharmacy_ade_in_octogenarian_with_new_dapt
    Polypharmacy ≥10 meds + Beers-list overlaps (NSAID, SSRI, steroid, anticholinergic) discovered while initiating DAPT — high ADE / bleed amplification risk
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Octogenarian NSTE-ACS conservative-strategy phenotype — gentler antiplatelet + bleed-mitigated AC + AKI-aware contrast plan; adds to parent cardio.nstemi.core.v1
axis: octogenarian_nsteacs_conservative_phenotype
Selected axis "Octogenarian NSTE-ACS conservative-strategy phenotype — gentler antiplatelet + bleed-mitigated AC + AKI-aware contrast plan; adds to parent cardio.nstemi.core.v1" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    162-325 mg load → 81 mg • PO chewed • load once → 81 mg daily lifelong unless major bleed
    triggers: nsteacs_in_age_ge_80
    Universal — ACC/AHA 2025 Class I; ISIS-2 mortality benefit; lifelong unless ARC-HBR major bleed event
    rxcui 1191
  • clopidogrel
    first line
    P2Y12_inhibitor
    300 mg load (consider 600 if PCI possible) → 75 mg daily • PO • daily × 3-12 mo per PRECISE-DAPT + MASTER DAPT
    triggers: octogenarian_nsteacs, arc_hbr_present, cfs_rockwood_ge_5
    Preferred P2Y12 in age ≥80 with frailty/HBR — better bleed profile than ticagrelor or prasugrel; ACC/AHA 2025 Class IIa for elderly HBR
    rxcui 32968
  • ticagrelor
    second line
    P2Y12_inhibitor
    180 mg load → 90 mg BID (consider 60 mg BID after 12 mo if continued per PEGASUS) • PO • BID × 12 mo if invasive elected and bleed risk acceptable
    triggers: octogenarian_nsteacs_pci_proceeded, no_high_bleed_risk, no_dyspnea_concern
    PLATO PMID 19717846 — net benefit preserved in elderly subgroup; reserve for non-HBR octogenarian who proceeded to PCI
    rxcui 1116632
  • fondaparinux
    first line
    parenteral_anticoagulant_factor_xa
    2.5 mg SC daily • SC • daily until end of hospitalisation or 8 d
    triggers: octogenarian_nsteacs_conservative_path, eGFR_ge_20
    OASIS-5 (Yusuf NEJM 2006 PMID 16554528) — fondaparinux 50% lower bleed vs enoxaparin in NSTE-ACS; preferred parenteral AC in elderly conservative path; ACC/AHA 2025 Class I
    rxcui 321208
  • enoxaparin
    second line
    LMWH
    1 mg/kg SC q12h (1 mg/kg q24h if CrCl 15-30) • SC • q12h or q24h per CrCl until cath or end of hospitalisation
    triggers: fondaparinux_unavailable, pci_likely
    ESSENCE PMID 11519503; renal dose-adjust mandatory in elderly; switch to UFH at PCI per ACC/AHA 2025
    rxcui 67108
  • atorvastatin
    first line
    statin_high_intensity
    80 mg (consider 40 mg if frailty CFS ≥6 or life-expectancy <2 y) • PO • daily
    triggers: octogenarian_nsteacs_confirmed
    PROVE-IT PMID 15007110 — start day 0; consider moderate-intensity in CFS ≥6 per shared decision (geriatric tolerability)
    rxcui 83367

outpatient playbook — drug actions (3)

  1. 1. de-escalate DAPT to ASA monotherapy at 3-6 mo if HBR
    aspirin 81 daily • PO • daily
    trigger: PRECISE-DAPT ≥25 OR ARC-HBR major OR bleed event during DAPT
    MASTER DAPT PMID 34516952 — 1 mo non-inferior; TWILIGHT PMID 31475798 — ticagrelor monotherapy after 3 mo HBR alternative
  2. 2. continue ASA + clopidogrel 12 mo if not HBR
    aspirin 81 + clopidogrel 75 • PO • daily
    trigger: No HBR + tolerated
    CURE PMID 11519503-trial-aliased; ACC/AHA 2025 Class I 12 mo standard
  3. 3. maintain low-dose GDMT
    atorvastatin 40-80 + BB low + ACEi low + MRA per renal/K • PO • daily
    trigger: Post-MI maintenance
    ACC/AHA 2025 Class I; geriatric tolerability

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Age ≥80 + NSTE-ACS confirmed by 0/1-h hsTn algorithm — shared-decision invasive vs conservative per ACC/AHA 2025; Clinical Frailty Scale (Rockwood) ≥5 — mild-moderate frailty drives risk-benefit toward conservative; Meets ARC-HBR major or 2 minor criteria → high bleed risk drives conservative + short DAPT (MASTER DAPT).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Octogenarian NSTE-ACS — conservative strategy** (cardio.nstemi.octogenarian-conservative.v1).
Phenotype framing: Type-1 vs type-2 MI per 4th UDMI; CKD + HFpEF + sepsis-related troponin elevation common in elderly; differential affects strategy
Scope: Confirm NSTE-ACS in age ≥80; flag elderly-specific shared decision (invasive vs conservative) per ACC/AHA 2025; route to parent cardio.nstemi.core.v1 for the universal regimen with elderly-specific antiplatelet + AKI + DAPT-duration overrides

No severity triggers fired against current inputs.

Plan

Regimen axis: **Octogenarian NSTE-ACS conservative-strategy phenotype — gentler antiplatelet + bleed-mitigated AC + AKI-aware contrast plan; adds to parent cardio.nstemi.core.v1**.
1. aspirin 162-325 mg load → 81 mg PO chewed load once → 81 mg daily lifelong unless major bleed (antiplatelet_cox1, first line) — Universal — ACC/AHA 2025 Class I; ISIS-2 mortality benefit; lifelong unless ARC-HBR major bleed event
2. clopidogrel 300 mg load (consider 600 if PCI possible) → 75 mg daily PO daily × 3-12 mo per PRECISE-DAPT + MASTER DAPT (P2Y12_inhibitor, first line) — Preferred P2Y12 in age ≥80 with frailty/HBR — better bleed profile than ticagrelor or prasugrel; ACC/AHA 2025 Class IIa for elderly HBR
3. ticagrelor 180 mg load → 90 mg BID (consider 60 mg BID after 12 mo if continued per PEGASUS) PO BID × 12 mo if invasive elected and bleed risk acceptable (P2Y12_inhibitor, second line) — PLATO PMID 19717846 — net benefit preserved in elderly subgroup; reserve for non-HBR octogenarian who proceeded to PCI
4. fondaparinux 2.5 mg SC daily SC daily until end of hospitalisation or 8 d (parenteral_anticoagulant_factor_xa, first line) — OASIS-5 (Yusuf NEJM 2006 PMID 16554528) — fondaparinux 50% lower bleed vs enoxaparin in NSTE-ACS; preferred parenteral AC in elderly conservative path; ACC/AHA 2025 Class I
5. enoxaparin 1 mg/kg SC q12h (1 mg/kg q24h if CrCl 15-30) SC q12h or q24h per CrCl until cath or end of hospitalisation (LMWH, second line) — ESSENCE PMID 11519503; renal dose-adjust mandatory in elderly; switch to UFH at PCI per ACC/AHA 2025
6. atorvastatin 80 mg (consider 40 mg if frailty CFS ≥6 or life-expectancy <2 y) PO daily (statin_high_intensity, first line) — PROVE-IT PMID 15007110 — start day 0; consider moderate-intensity in CFS ≥6 per shared decision (geriatric tolerability)

Setting playbook (outpatient) — 3-12 mo follow-up — DAPT-duration decision per PRECISE-DAPT + bleed event history; long-term GDMT optimisation balanced with frailty trajectory; cross-link to geriatrics + chronic CAD engines
7. de-escalate DAPT to ASA monotherapy at 3-6 mo if HBR aspirin 81 daily PO daily — PRECISE-DAPT ≥25 OR ARC-HBR major OR bleed event during DAPT (MASTER DAPT PMID 34516952 — 1 mo non-inferior; TWILIGHT PMID 31475798 — ticagrelor monotherapy after 3 mo HBR alternative)
8. continue ASA + clopidogrel 12 mo if not HBR aspirin 81 + clopidogrel 75 PO daily — No HBR + tolerated (CURE PMID 11519503-trial-aliased; ACC/AHA 2025 Class I 12 mo standard)
9. maintain low-dose GDMT atorvastatin 40-80 + BB low + ACEi low + MRA per renal/K PO daily — Post-MI maintenance (ACC/AHA 2025 Class I; geriatric tolerability)

Non-pharmacologic actions:
- Reinforce daily BP + symptom log
- Cardiac rehab maintenance phase if functional
- Annual flu + COVID vaccination, pneumococcal per CDC
- Annual cognitive + functional screen
- Falls prevention review every visit

AVOID / contraindication checks:
- Prasugrel block if age above 75 or weight below 60kg (FDA boxed warning; TRITON TIMI 38 elderly subgroup harm)
- Antithrombotic block if active bleeding (ACC/AHA 2025 Class III)
- Fondaparinux block if egfr below 20 (label)
- Enoxaparin renal dose adjust q24h if crcl 15 30 (ACC/AHA 2025)
- Nsaid and ssri and steroid bleed amplification warning (Beers 2023)

Monitoring

Regimen monitoring:
- Hgb baseline then q12h × 24 h on triple antithrombotic (ARC-HBR + BARC 2011)
- Platelets baseline then q3d (HIT screening)
- Creatinine baseline + q24h (KDIGO 2026 AKI prophylaxis)
- Daily delirium screen (CAM) — antiplatelet effect on cognition negligible but identifies confounders
- Falls precautions on bleed-risk units

Setting (outpatient) monitoring:
- BMP every 3 mo on ACEi/MRA
- Lipid panel every 6-12 mo — target LDL <70 (with shared-decision override for very frail)
- Bleeding signs check at every visit through DAPT duration
- Hgb annually — anemia common in elderly + bleed-amplifier

Follow-up plan: Cardiac rehab (geriatric-tailored) Class I; lipid recheck 4-8 wks; PRECISE-DAPT-driven DAPT duration (3-6 mo if HBR per MASTER DAPT) with explicit reassessment cadence; geriatrics co-management if frail
- Close-out criterion: Discharge bundle + cardiac rehab booked + DAPT-duration plan documented

Monitoring phase: Continuous ECG + SpO2; daily Hgb + BMP first 48 h; bleeding signs each shift per BARC 2011; falls precautions; delirium screen (CAM) q shift; mobility + nutrition supportive

Disposition

Current setting: outpatient — 3-12 mo follow-up — DAPT-duration decision per PRECISE-DAPT + bleed event history; long-term GDMT optimisation balanced with frailty trajectory; cross-link to geriatrics + chronic CAD engines

Disposition criteria:
- Long-term continuation; cross-link to cardio.hf.core.v1 if HFrEF persists; geriatrics-PCP shared model if CFS ≥5

Escalation triggers (move to higher acuity):
- Recurrent chest pain → ED + reassess invasive vs conservative
- BARC 2+ bleed → de-escalate DAPT immediately
- NYHA worsening to III+ → expedite cardiology re-eval + echo
- Functional decline / fall with injury → pause titration, geriatric reassessment

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] SBP <90 with hypoperfusion OR sustained VT/VF in octogenarian NSTE-ACS — overrides conservative shared decision and re-frames toward invasive (functional baseline permitting)
- [SEVERE] BARC 3+ or BARC 2 with hemodynamic compromise during DAPT in octogenarian NSTE-ACS — gates immediate antiplatelet hold + bleed source workup + DAPT-duration shortening
- [SEVERE] eGFR <30 + cath being considered in octogenarian — high contrast nephropathy + dialysis-initiation risk

Citations

- 2025 ACC/AHA Guideline for ACS (Rao) — elderly + frail section; ESC 2023 NSTE-ACS Guideline (Byrne, PMID 37622670) [PMID:37622670](https://pubmed.ncbi.nlm.nih.gov/37622670/)
- Cited evidence (PMID 32605898) [PMID:32605898](https://pubmed.ncbi.nlm.nih.gov/32605898/)
- Cited evidence (PMID 26794722) [PMID:26794722](https://pubmed.ncbi.nlm.nih.gov/26794722/)
- Cited evidence (PMID 16129869) [PMID:16129869](https://pubmed.ncbi.nlm.nih.gov/16129869/)
- Cited evidence (PMID 11253156) [PMID:11253156](https://pubmed.ncbi.nlm.nih.gov/11253156/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA Guideline for ACS (Rao) — elderly + frail section; ESC 2023 NSTE-ACS Guideline (Byrne, PMID 37622670) — PMID:37622670
  • Cited evidence (PMID 32605898) — PMID:32605898
  • Cited evidence (PMID 26794722) — PMID:26794722
  • Cited evidence (PMID 16129869) — PMID:16129869
  • Cited evidence (PMID 11253156) — PMID:11253156